Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy
intellia therapeutics 宣佈FDA授予Nexiguran Ziclumeran (Nex-Z)用於治療遺傳性轉甲狀腺素（ATTR）澱粉樣變性的再生醫學先進療法（RMAT）認證，伴有多發性神經病
